admin – Page 6139 – Get News Story

Leading Real Estate Agent in Durham, NC, Highlights the Rise of Cash Buyers in a Competitive Market

Steed Rollins, a top real estate agent in Durham, NC, is shedding light on a significant trend that is shaping the local housing market – the increasing dominance of cash buyers. This trend is especially prevalent in Durham’s competitive segments, where the speed and simplicity of cash transactions are highly prized. “Cash buyers are becoming more common in our market, and their presence is changing the dynamics of buying and selling homes,” Steed notes, emphasizing the need for both buyers and sellers to understand this shift.

With his extensive experience, Steed advises sellers on how to attract these cash buyers, who often prefer transactions that can close quickly and without the typical financing contingencies. “Attracting a cash buyer can significantly simplify the selling process and reduce the time your home spends on the market,” explains Steed, a knowledgeable Realtor in Durham, NC. He works closely with sellers to market their properties effectively to this group, highlighting features that are particularly appealing to investors and those looking for a straightforward purchase.

For buyers, particularly those who are not paying in cash, Steed provides strategies to remain competitive. This includes ensuring financial pre-approval and readiness to make decisive, timely offers. “Even if you’re not a cash buyer, being well-prepared and able to move quickly can make you a more attractive candidate in this market,” says Steed, whose advice is invaluable for anyone navigating Durham’s fast-paced real estate environment.

As a real estate listing agent in Durham, NC, Steed’s expertise is crucial for clients looking to navigate the complexities of a market influenced by cash transactions. His approach not only helps sellers maximize their sale potential but also aids buyers in understanding how to effectively compete.

For those interested in buying or selling in Durham, particularly in a market with a high volume of cash transactions, visiting http://steedrollins.com/ is a great first step. Here, Steed Rollins offers professional guidance and detailed market insights. “Contact us to explore how we can help you succeed in Durham’s dynamic real estate market,” Steed encourages, inviting potential clients to leverage his deep market knowledge and extensive network.

Media Contact
Company Name: Steed Rollins Realtor | Real Estate Agent in Durham NC
Contact Person: Steed Rollins
Email: Send Email
Phone: +1 919-306-9767
Address:112 Montrose Dr.
City: Durham
State: North Carolina 27707
Country: United States
Website: http://steedrollins.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Leading Real Estate Agent in Durham, NC, Highlights the Rise of Cash Buyers in a Competitive Market

Top Realtor in Tahoe City, CA, Revolutionizes Property Potential with Unique Home Transformation Expertise

Jennifer Borwick, known by locals as one of the top Realtors in Tahoe City, CA, is renowned for revolutionizing the potential of properties through her unique home transformation expertise. With a decade of real estate experience, Jennifer’s background as a nurse and owner of a staging and design firm has imbued her with a rare and valuable skill set. This combination allows her to uniquely assist both buyers and sellers by maximizing and realizing the potential of each home she handles.

“My approach is about more than just buying and selling; it’s about re-envisioning what a home can be. This perspective is crucial in helping my clients see beyond the present and imagine the future,” Jennifer explains. Her ability to transform homes according to the latest market trends and individual client needs sets her apart from other real estate agents in Tahoe City, CA.

For sellers, Jennifer offers a hands-on staging service that enhances the visual appeal and functionality of their homes, ensuring they attract premium offers. Her meticulous attention to detail and deep understanding of buyer preferences enable her to effectively market properties that stand out in the competitive Tahoe City real estate market. For buyers, her insights into home potential help them envision what each property could become, making her an invaluable guide in their search for the perfect home.

As a seasoned real estate selling agent in Tahoe City, CA, Jennifer prides herself on her ability to handle complex transactions with professionalism and a personal touch. “Whether you’re looking to sell at top dollar or find a home that you can turn into your dream space, I am here to make that happen,” Jennifer states confidently.

To explore how Jennifer can transform your property experience in Tahoe City, visit https://www.dreamlivinglaketahoe.com/. Working with Jennifer Borwick means experiencing firsthand her exceptional ability to unleash property potential. Whether selling or buying, Jennifer’s expertise ensures that every client achieves their real estate goals with extraordinary outcomes. As one of the top Realtors in the area, Jennifer transforms not just homes but lives, by delivering unmatched service and results.

Media Contact
Company Name: Dream Living Lake Tahoe | Real Estate Agent in Tahoe City CA
Contact Person: Jennifer Borwick
Email: Send Email
Phone: +1 530-386-7502
Address:531 N Lake Blvd # A
City: Tahoe City
State: California 96145
Country: United States
Website: https://www.dreamlivinglaketahoe.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Top Realtor in Tahoe City, CA, Revolutionizes Property Potential with Unique Home Transformation Expertise

Diabetic Kidney Disease Market Forecast 2034: Clinical Trials, Epidemiology, FDA Approvals, Therapies, and Companies by DelveInsight

“Diabetic Kidney Disease Market”

Diabetic Kidney Disease companies are Daiichi Sankyo, Prokidney, Astrazeneca, Palatin, Teijin Pharma, Chugai Pharmaceutical, Bayer, Chinook Therapeutics, Dimerix, CSL Behring, Novartis, Mineralys Therapeutics, Boehringer Ingelheim, Inversago Pharma, and others.

(Albany, USA) DelveInsight’s “Diabetic Kidney Disease Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of Diabetic Kidney Disease, historical and forecasted epidemiology as well as the Diabetic Kidney Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Diabetic Kidney Disease market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Diabetic Kidney Disease market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Diabetic Kidney Disease treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Diabetic Kidney Disease market.

Request for a Free Sample Report @ Diabetic Kidney Disease Market Forecast

Some facts of the Diabetic Kidney Disease Market Report are:

According to DelveInsight, Diabetic Kidney Disease market size is expected to grow at a decent CAGR by 2034.
The total Diabetic Kidney Disease market size in the 7MM is approximately USD ~7,200 million in 2023 and is projected to increase during the forecast period (2023–2034).
Leading Diabetic Kidney Disease companies working in the market are Daiichi Sankyo, Prokidney, Astrazeneca, Palatin, Teijin Pharma, Chugai Pharmaceutical, Bayer, Chinook Therapeutics, Dimerix, CSL Behring, Novartis, Mineralys Therapeutics, Boehringer Ingelheim, Inversago Pharma, and others.
Key Diabetic Kidney Disease Therapies expected to launch in the market are REACT, Esaxerenone (CS-3150), SER150, Atrasentan, Zibotentan + dapagliflozin, BI 690517 ± empagliflozin, CSL346, and others.

Diabetic Kidney Disease Overview

Diabetic Kidney Disease (DKD) is a common complication of diabetes and a leading cause of end-stage kidney disease (ESKD). It results from long-term damage to the kidneys’ small blood vessels. DKD typically progresses silently over many years, manifesting initially as microalbuminuria (small amounts of protein in the urine) and eventually leading to macroalbuminuria (larger protein excretion) and declining kidney function. Risk factors for DKD include poor glycemic control, hypertension, genetics, and smoking. Early detection and intervention are critical to slow progression and reduce complications. Management strategies focus on controlling blood sugar and blood pressure levels, along with lifestyle modifications such as diet and exercise. Medications targeting the renin-angiotensin-aldosterone system (RAAS) have demonstrated efficacy in slowing DKD progression. In advanced stages, dialysis or kidney transplantation may be necessary for survival. Preventive measures, including regular screening and adherence to treatment plans, are essential in managing DKD effectively and improving outcomes for individuals with diabetes.

Learn more about Diabetic Kidney Disease treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Diabetic Kidney Disease Treatment Market

Diabetic Kidney Disease Market

The Diabetic Kidney Disease market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Diabetic Kidney Disease market trends by analyzing the impact of current Diabetic Kidney Disease therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Diabetic Kidney Disease market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Diabetic Kidney Disease market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Diabetic Kidney Disease market in 7MM is expected to witness a major change in the study period 2020-2034.

Diabetic Kidney Disease Epidemiology

The Diabetic Kidney Disease epidemiology section provides insights into the historical and current Diabetic Kidney Disease patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Diabetic Kidney Disease market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Diabetic Kidney Disease Epidemiology @ Diabetic Kidney Disease Prevalence

Diabetic Kidney Disease Drugs Uptake

This section focuses on the uptake rate of the potential Diabetic Kidney Disease drugs recently launched in the Diabetic Kidney Disease market or expected to be launched in 2020-2034. The analysis covers the Diabetic Kidney Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Diabetic Kidney Disease Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Diabetic Kidney Disease market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Diabetic Kidney Disease Pipeline Development Activities

The Diabetic Kidney Disease report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Diabetic Kidney Disease key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Diabetic Kidney Disease pipeline development activities @ Diabetic Kidney Disease Therapies and Drugs

Diabetic Kidney Disease Therapeutics Assessment

Major key companies are working proactively in the Diabetic Kidney Disease Therapeutics market to develop novel therapies which will drive the Diabetic Kidney Disease treatment markets in the upcoming years are Daiichi Sankyo, Prokidney, Astrazeneca, Palatin, Teijin Pharma, Chugai Pharmaceutical, Bayer, Chinook Therapeutics, Dimerix, CSL Behring, Novartis, Mineralys Therapeutics, Boehringer Ingelheim, Inversago Pharma, and others.

Learn more about the emerging Diabetic Kidney Disease therapies & key companies @ Diabetic Kidney Disease Clinical Trials and FDA Approvals

Diabetic Kidney Disease Report Key Insights

1. Diabetic Kidney Disease Patient Population

2. Diabetic Kidney Disease Market Size and Trends

3. Key Cross Competition in the Diabetic Kidney Disease Market

4. Diabetic Kidney Disease Market Dynamics (Key Drivers and Barriers)

5. Diabetic Kidney Disease Market Opportunities

6. Diabetic Kidney Disease Therapeutic Approaches

7. Diabetic Kidney Disease Pipeline Analysis

8. Diabetic Kidney Disease Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Diabetic Kidney Disease Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Diabetic Kidney Disease Competitive Intelligence Analysis

4. Diabetic Kidney Disease Market Overview at a Glance

5. Diabetic Kidney Disease Disease Background and Overview

6. Diabetic Kidney Disease Patient Journey

7. Diabetic Kidney Disease Epidemiology and Patient Population

8. Diabetic Kidney Disease Treatment Algorithm, Current Treatment, and Medical Practices

9. Diabetic Kidney Disease Unmet Needs

10. Key Endpoints of Diabetic Kidney Disease Treatment

11. Diabetic Kidney Disease Marketed Products

12. Diabetic Kidney Disease Emerging Therapies

13. Diabetic Kidney Disease Seven Major Market Analysis

14. Attribute Analysis

15. Diabetic Kidney Disease Market Outlook (7 major markets)

16. Diabetic Kidney Disease Access and Reimbursement Overview

17. KOL Views on the Diabetic Kidney Disease Market

18. Diabetic Kidney Disease Market Drivers

19. Diabetic Kidney Disease Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432, Las Vegas NV 89107
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/asco-conference-coverage

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Diabetic Kidney Disease Market Forecast 2034: Clinical Trials, Epidemiology, FDA Approvals, Therapies, and Companies by DelveInsight

Top Realtor in Morro Bay, CA Presents a Rare Opportunity: Eco-Friendly Luxury Home with Potential ADU Conversion

Joel Pace, a top Realtor in Morro Bay, CA, is proud to present an exceptional off-market opportunity that exemplifies luxury and sustainability. This newly constructed 4-bedroom, 3-bath home, designed with eco-conscious features and the potential for an Accessory Dwelling Unit (ADU) conversion, offers a rare blend of opulence and eco-friendly living. Situated in the heart of Morro Bay, this stunning property promises an upscale lifestyle with breathtaking ocean views and state-of-the-art amenities.

“This home is the epitome of modern luxury living,” Joel explains. “From its high-end Samsung appliances and quartz countertops to the large 7.6 kWh solar electric system that powers the entire house – including a Tesla EV charger – it’s designed to impress while minimizing environmental impact.” The property also features all-electric central heating and air conditioning, luxury vinyl plank flooring throughout, and soft-close shaker cabinets, ensuring every detail contributes to both comfort and sustainability.

The innovative design of this home extends to its outdoor spaces, where an extra-large covered deck offers expansive views of the ocean, perfect for entertaining guests or enjoying peaceful sunsets. Joel, an experienced real estate listing agent in Morro Bay, CA, emphasizes the versatility of the property, noting, “The thoughtful layout includes the possibility of converting part of the space into an ADU, making it an ideal solution for families looking for additional income or separate living quarters.”

As a dedicated real estate agent in Morro Bay, CA, Joel understands the value of such a unique property in today’s market. “For those who desire a luxurious yet sustainable lifestyle, this home represents a perfect opportunity to enjoy the best of both worlds,” he adds.

For more information about this exquisite new construction in Morro Bay, or to schedule a private showing, visit https://www.joelpacerealestate.com/. This is your chance to own a cutting-edge, eco-friendly home that does not compromise on luxury or location. Don’t miss out on this exclusive offering in one of California’s most scenic coastal towns. Contact Joel Pace today and take the first step towards owning your dream eco-luxury home in Morro Bay.

Media Contact
Company Name: Joel Pace Real Estate Agent in Morro Bay, CA
Contact Person: Joel Pace
Email: Send Email
Phone: +1 (805) 703-0778
Address:317 Morro Bay Blvd
City: Morro Bay
State: California 93442
Country: United States
Website: http://joelpacerealestate.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Top Realtor in Morro Bay, CA Presents a Rare Opportunity: Eco-Friendly Luxury Home with Potential ADU Conversion

Breast Cancer Market Forecast 2032: Clinical Trials, Epidemiology, FDA Approvals, Therapies, and Companies by DelveInsight

“Breast Cancer Market”

Breast Cancer companies are Veru, Sanofi, Roche, AstraZeneca, Eli Lilly, EQRx, Gilead, Sermonix Pharmaceuticals, Evgen Pharma, Tyme, Genentech, Daiichi Sankyo, Pfizer, and others.

(Albany, USA) DelveInsight’s “Breast Cancer Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Breast Cancer, historical and forecasted epidemiology as well as the Breast Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Breast Cancer market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Breast Cancer market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Breast Cancer treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Breast Cancer market.

Request for a Free Sample Report @ Breast Cancer Market Forecast

Some facts of the Breast Cancer Market Report are:

According to DelveInsight, Breast Cancer market size is expected to grow at a decent CAGR by 2032.
Leading Breast Cancer companies working in the market are Veru, Sanofi, Roche, AstraZeneca, Eli Lilly, EQRx, Gilead, Sermonix Pharmaceuticals, Evgen Pharma, Tyme, Genentech, DaiichiSankyo, Pfizer Inc., AstraZeneca, Novartis AG, Merck, Sanofi, Bristol-Myers Squibb, Eisai, Mylan N.V., Teva Pharmaceutical, Kyowa Kirin Co., Ltd., MacroGenics, Inc., Gilead Sciences, Takeda Pharmaceutical Company Limited, and AbbVie Inc. and others.
Key Breast Cancer Therapies expected to launch in the market are Camizestrant (AZD9833), Lasofoxifene, IBRANCE (palbociclib), LYNPARZA (olaparib), and others.
In November 2023, Pfizer announces that its new breast cancer drug, palbociclib, has been approved by the FDA for the treatment of patients with HER2-positive metastatic breast cancer. Palbociclib is a CDK4/6 inhibitor that works by blocking the growth and spread of cancer cells.Merck announces that its new breast cancer drug, pembrolizumab, has been approved by the FDA for the treatment of patients with triple-negative breast cancer (TNBC). Pembrolizumab is an immunotherapy drug that works by boosting the body’s immune system to fight cancer cells. Roche announces that its new breast cancer drug, tucatinib, has been approved by the FDA for the treatment of patients with HER2-positive advanced or metastatic breast cancer. Tucatinib is a TKI that works by blocking the HER2 protein, which is involved in the growth and spread of cancer cells.

Breast Cancer Overview

Breast cancer forms when cells in the breast mutate and grow uncontrollably. It is the most common cancer among women globally. While it primarily affects women, men can also develop breast cancer, though it’s rare. Risk factors include age, family history, genetic mutations (such as BRCA1 and BRCA2), hormonal factors (early menstruation, late menopause, hormone replacement therapy), obesity, alcohol consumption, and radiation exposure. Symptoms may include a lump in the breast, changes in breast size or shape, dimpling of the breast skin, nipple discharge, or nipple inversion. Diagnosis involves mammograms, ultrasounds, MRIs, and biopsies. Treatment options vary based on the stage and type of cancer but may include surgery, chemotherapy, radiation therapy, hormone therapy, targeted therapy, or a combination. Early detection through screening and advancements in treatment have significantly improved survival rates and quality of life for those with breast cancer.

Learn more about Breast Cancer treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Breast Cancer Treatment Market

Breast Cancer Market

The Breast Cancer market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Breast Cancer market trends by analyzing the impact of current Breast Cancer therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Breast Cancer market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Breast Cancer market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Breast Cancer market in 7MM is expected to witness a major change in the study period 2019-2032.

Breast Cancer Epidemiology

The Breast Cancer epidemiology section provides insights into the historical and current Breast Cancer patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Breast Cancer market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Breast Cancer Epidemiology @ Breast Cancer Incidence

Breast Cancer Drugs Uptake

This section focuses on the uptake rate of the potential Breast Cancer drugs recently launched in the Breast Cancer market or expected to be launched in 2019-2032. The analysis covers the Breast Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.

Breast Cancer Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Breast Cancer market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Breast Cancer Pipeline Development Activities

The Breast Cancer report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Breast Cancer key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Breast Cancer pipeline development activities @ Breast Cancer Therapies and Drugs

Breast Cancer Therapeutics Assessment

Major key companies are working proactively in the Breast Cancer Therapeutics market to develop novel therapies which will drive the Breast Cancer treatment markets in the upcoming years are Veru, Sanofi, Roche, AstraZeneca, Eli Lilly, EQRx, Gilead, Sermonix Pharmaceuticals, Evgen Pharma, Tyme, Genentech, DaiichiSankyo, Pfizer Inc., AstraZeneca, Novartis AG, Merck, Sanofi, Bristol-Myers Squibb, Eisai, Mylan N.V., Teva Pharmaceutical, Kyowa Kirin Co., Ltd., MacroGenics, Inc., Gilead Sciences, Takeda Pharmaceutical Company Limited, and AbbVie Inc. and others.

Learn more about the emerging Breast Cancer therapies & key companies @ Breast Cancer Clinical Trials and FDA Approvals

Breast Cancer Report Key Insights

1. Breast Cancer Patient Population

2. Breast Cancer Market Size and Trends

3. Key Cross Competition in the Breast Cancer Market

4. Breast Cancer Market Dynamics (Key Drivers and Barriers)

5. Breast Cancer Market Opportunities

6. Breast Cancer Therapeutic Approaches

7. Breast Cancer Pipeline Analysis

8. Breast Cancer Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Breast Cancer Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Breast Cancer Competitive Intelligence Analysis

4. Breast Cancer Market Overview at a Glance

5. Breast Cancer Disease Background and Overview

6. Breast Cancer Patient Journey

7. Breast Cancer Epidemiology and Patient Population

8. Breast Cancer Treatment Algorithm, Current Treatment, and Medical Practices

9. Breast Cancer Unmet Needs

10. Key Endpoints of Breast Cancer Treatment

11. Breast Cancer Marketed Products

12. Breast Cancer Emerging Therapies

13. Breast Cancer Seven Major Market Analysis

14. Attribute Analysis

15. Breast Cancer Market Outlook (7 major markets)

16. Breast Cancer Access and Reimbursement Overview

17. KOL Views on the Breast Cancer Market

18. Breast Cancer Market Drivers

19. Breast Cancer Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Breast Cancer Market Forecast 2032: Clinical Trials, Epidemiology, FDA Approvals, Therapies, and Companies by DelveInsight

Primary Hyperoxaluria Market Forecast 2032: Clinical Trials, Epidemiology, FDA Approvals, Therapies, and Companies by DelveInsight

“Primary Hyperoxaluria Market”

Primary Hyperoxaluria Companies are Oxthera, Allena Pharmaceuticals, Dicerna Pharmaceuticals, Inc., Allena Pharmaceuticals, and others.

(Albany, USA) DelveInsight’s “Primary Hyperoxaluria Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Primary Hyperoxaluria, historical and forecasted epidemiology as well as the Primary Hyperoxaluria market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Primary Hyperoxaluria market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Primary Hyperoxaluria market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Primary Hyperoxaluria treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Primary Hyperoxaluria market.

Request for a Free Sample Report @ Primary Hyperoxaluria Market Insight

Some facts of Primary Hyperoxaluria market report are:

According to DelveInsight’s analysis, the market size for primary hyperoxaluria reached USD 81 million in 2021 across the 7MM and is expected to grow with a significant CAGR by 2032.
DelveInsight’s analysis reveals that the overall prevalent population of primary hyperoxaluria in the 7MM was reported as ~12K in 2021.
Prominent companies working in the domain of primary hyperoxaluria, including Alnylam Pharmaceuticals, Dicerna Pharmaceuticals, OxThera, Allena Pharmaceuticals, Biocodex, and others, are actively working on innovative drugs for primary hyperoxaluria. These novel primary hyperoxaluria therapies are anticipated to enter the primary hyperoxaluria market in the forecast period and are expected to change the market.
Some of the key therapies for primary hyperoxaluria treatment include Lumasiran, DCR-PHXC, Oxabact (OC5-DB-02), Reloxaliase (ALLN-177), Stiripentol (Diacomit), and others.

Primary Hyperoxaluria Overview

Primary Hyperoxaluria (PH) is a rare genetic disorder characterized by the overproduction of oxalate, a substance that combines with calcium to form kidney and urinary tract stones. This condition arises due to mutations in genes responsible for enzymes that help process glyoxylate, leading to its conversion into oxalate instead. The three known types— Primary Hyperoxaluria 1, Primary Hyperoxaluria 2, and Primary Hyperoxaluria 3—are caused by mutations in the AGXT, GRHPR, and HOGA1 genes, respectively.

Primary Hyperoxaluria often manifests in childhood with recurrent kidney stones, urinary tract infections, and potential kidney damage. As the disease progresses, excessive oxalate can accumulate in bones, eyes, heart, and skin, leading to a condition called oxalosis. Severe cases may result in end-stage renal disease (ESRD), necessitating dialysis or kidney transplantation.

Primary Hyperoxaluria Diagnosis typically involves genetic testing, urine analysis for oxalate levels, and liver enzyme assays. Early detection is crucial for managing the condition and preventing complications. Primary Hyperoxaluria Treatment strategies focus on reducing oxalate levels through high fluid intake, low-oxalate diet, and medications like potassium citrate. In advanced cases, combined liver and kidney transplantation may be necessary.

Ongoing research aims to develop gene therapies and other novel treatments to better manage and potentially cure Primary Hyperoxaluria, improving the quality of life for affected individuals.

Learn more about Primary Hyperoxaluria treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Primary Hyperoxaluria Treatment Market

Primary Hyperoxaluria Market

The Primary Hyperoxaluria market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Primary Hyperoxaluria market trends by analyzing the impact of current Primary Hyperoxaluria therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Primary Hyperoxaluria market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Primary Hyperoxaluria market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Primary Hyperoxaluria market in 7MM is expected to witness a major change in the study period 2019-2032.

Primary Hyperoxaluria Epidemiology

The Primary Hyperoxaluria epidemiology section provides insights into the historical and current Primary Hyperoxaluria patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Primary Hyperoxaluria market report also provides the diagnosed patient pool, trends, and assumptions.

Primary Hyperoxaluria Epidemiology Segmentation:

Primary Hyperoxaluria Prevalent Cases
Diagnosed Primary Hyperoxaluria Prevalent Cases
Gender-specific Primary Hyperoxaluria Diagnosed Prevalent Cases
Age-specific Diagnosed Primary Hyperoxaluria Prevalent Cases
Type-specific Diagnosed Primary Hyperoxaluria Prevalent Cases

Explore more about Primary Hyperoxaluria Epidemiology @ Primary Hyperoxaluria Prevalence

Primary Hyperoxaluria Drugs Uptake

This section focuses on the uptake rate of the potential Primary Hyperoxaluria drugs recently launched in the Primary Hyperoxaluria market or expected to be launched in 2019-2032. The analysis covers the Primary Hyperoxaluria market uptake by drugs, patient uptake by therapies, and sales of each drug.

Primary Hyperoxaluria Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Primary Hyperoxaluria market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Primary Hyperoxaluria Pipeline Development Activities

The Primary Hyperoxaluria report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Primary Hyperoxaluria key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Primary Hyperoxaluria pipeline development activities @ Primary Hyperoxaluria Therapies and Drugs

Primary Hyperoxaluria Therapeutics Assessment

Major key companies are working proactively in the Primary Hyperoxaluria Therapeutics market to develop novel therapies which will drive the Primary Hyperoxaluria treatment markets in the upcoming years are Oxthera, Allena Pharmaceuticals, Dicerna Pharmaceuticals, Inc., Allena Pharmaceuticals, Biocodex, and others.

Learn more about the emerging Primary Hyperoxaluria therapies & key companies @ Primary Hyperoxaluria Clinical Trials and FDA Approvals

Primary Hyperoxaluria Report Key Insights

1. Primary Hyperoxaluria Patient Population

2. Primary Hyperoxaluria Market Size and Trends

3. Key Cross Competition in the Primary Hyperoxaluria Market

4. Primary Hyperoxaluria Market Dynamics (Key Drivers and Barriers)

5. Primary Hyperoxaluria Market Opportunities

6. Primary Hyperoxaluria Therapeutic Approaches

7. Primary Hyperoxaluria Pipeline Analysis

8. Primary Hyperoxaluria Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Primary Hyperoxaluria Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Primary Hyperoxaluria Competitive Intelligence Analysis

4. Primary Hyperoxaluria Market Overview at a Glance

5. Primary Hyperoxaluria Disease Background and Overview

6. Primary Hyperoxaluria Patient Journey

7. Primary Hyperoxaluria Epidemiology and Patient Population

8. Primary Hyperoxaluria Treatment Algorithm, Current Treatment, and Medical Practices

9. Primary Hyperoxaluria Unmet Needs

10. Key Endpoints of Primary Hyperoxaluria Treatment

11. Primary Hyperoxaluria Marketed Products

12. Primary Hyperoxaluria Emerging Therapies

13. Primary Hyperoxaluria Seven Major Market Analysis

14. Attribute Analysis

15. Primary Hyperoxaluria Market Outlook (7 major markets)

16. Primary Hyperoxaluria Access and Reimbursement Overview

17. KOL Views on the Primary Hyperoxaluria Market

18. Primary Hyperoxaluria Market Drivers

19. Primary Hyperoxaluria Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Primary Hyperoxaluria Market Forecast 2032: Clinical Trials, Epidemiology, FDA Approvals, Therapies, and Companies by DelveInsight

Athleisure and Luxury Fuse to Lead Consumer Trends (AXIL, LULU, NKE, YETI)

Modern consumer fashion trends have been highlighted by growth in a space where athleisure meets luxury. Nowhere has this trend been more pronounced than in Lululemon’s (NASDAQ: LULU) decade long surge to leadership amongst multi-generational consumers seeking an active casual lifestyle, while clearly stating, “this look didn’t come cheap.”

Modern consumer fashion trends have been highlighted by growth in a space where athleisure meets luxury. Nowhere has this trend been more pronounced than in Lululemon’s (NASDAQ: LULU) decade long surge to leadership amongst multi-generational consumers seeking an active casual lifestyle, while clearly stating, “this look didn’t come cheap.” Despite brand maturity, this movement has allowed Lululemon to post double digit growth in revenue and earnings, whereas competitor Nike (NYSE:NKE) failed to post single digit revenue growth and saw a slight reduction in their earnings YOY, yet maintained strong positive cash flow and profitability.

Recently athleisure or the ideology that a successful trendsetter balancing career, family and health goals isn’t confined to just fashion apparel and has spilled over into the consumer’s personal electronics choices and outdoor recreation equipment and apparel. On the personal electronics front, AXIL Brands Inc. (NYSE American: AXIL) have leveraged their approach to multi-functional fashionable Bluetooth ear buds with built in hearing protection and enhancement to complement the athleisure trend, making their way into the 2024 Paris Summer Olympic Games, NASCAR stadiums, personal fitness routines and concert venues, among other indoor and outdoor leisure activities and recently posting triple digit earnings growth last quarter and high double digit revenue growth for the last two years. YETI Holdings, Inc. (NYSE: YETI) has entered the athleisure space by defining high quality luxury coolers and utilizing their branding success to pivot into high quality apparel, among other offerings complimentary to the freedom offered by outdoor healthy living activities. YETI’s pivot has kept them on trend with Lululemon’s double digit revenue and earnings growth, and all of these companies have built on the common theme that quality offerings designed to enhance quality of life lead to a healthier bottom line and a healthier consumer.

Disclaimers: RazorPitch Inc. “RazorPitch” is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by ITMM Consulting to distribute this content related to AXIL. RazorPitch is not responsible for the production of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content.

Media Contact
Company Name: RazorPitch
Contact Person: Mark McKelvie
Email: Send Email
City: NAPLES
State: Florida
Country: United States
Website: https://razorpitch.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Athleisure and Luxury Fuse to Lead Consumer Trends (AXIL, LULU, NKE, YETI)

CloudMile Wins MongoDB Emerging Markets Partner of the Year Award for Driving Data Innovation and Business Impact in Southeast Asia

June 25, 2024 – Southeast Asia – CloudMile, a leading AI and cloud technology company in Southeast Asia (SEA), today announced that it has received the 2024 MongoDB Emerging Markets Partner of the Year award. The award recognizes CloudMile’s contributions to pushing SEA’s data modernization efforts forward, and the success CloudMile and MongoDB have had growing business across the region.

As companies increasingly focus on generative AI, how they manage and operationalize their data has become ever more crucial. Data silos and slow response times can significantly impact AI performance – as well as the development of AI applications. Because it securely unifies operational, unstructured, and AI-related data, MongoDB Atlas streamlines building AI-enriched applications and helps companies like CloudMile unlock innovation.

The MongoDB Emerging Markets Partner of the Year award was designed to honor partners like CloudMile who have demonstrated exceptional expertise and have achieved remarkable results in expanding the reach of MongoDB-based solutions in high-growth markets.

“We are deeply honored to receive the MongoDB Emerging Markets Partner of the Year award,” said Jeremy Heng, SEA Lead, CloudMile. “This recognition is a testament to our team’s relentless dedication, deep MongoDB expertise, and unwavering focus on delivering transformative data and AI solutions to our clients. As we continue our journey of helping organizations leverage data and AI to drive transformative change, we remain committed to our partnership with MongoDB and to delivering cutting-edge solutions that unlock new possibilities for customers.”

Since partnering with MongoDB in 2023, CloudMile has worked closely with MongoDB to deliver innovative solutions for a range of enterprise clients. By combining CloudMile’s expertise in cloud technologies and data engineering with the flexibility and scalability of MongoDB Atlas, the two companies have been able to drive transformative outcomes for their joint customers.

One prominent example is CloudMile’s work with a leading gaming company in APAC with over 1 million active members. The gaming company struggled with the limitations of traditional relational databases, which hindered its ability to provide a seamless, engaging experience for its vast player base. By leveraging the power of MongoDB Atlas, CloudMile helped the gaming company overcome the constraints of legacy databases. This enabled the company to more effectively manage and analyze its rapidly growing data, leading to a dramatic improvement in user experience and customer satisfaction.

“Our partnership with CloudMile hit the ground running last year, and it was clear from the start that they shared our passion for helping customers in the region find the right technology to innovate quickly,” said Stewart Garrett, Regional Vice President, ASEAN and Japan, MongoDB. “Working closely with CloudMile, we’re able to be part of the solution that helps businesses in growing markets incorporate the latest generative AI solutions into their tech stack to enable the development of next-generation applications. It’s our sincere pleasure to recognize their efforts with this year’s MongoDB Emerging Markets Partner of the Year award.”

The MongoDB Emerging Markets Partner of the Year award adds to CloudMile’s growing list of accolades and industry recognition. Earlier this year, the company was also named a Google Cloud Sales & Services Partner of the Year for Singapore, as well as the Google Cloud Social Impact Partner of the Year for APAC, highlighting the company’s excellence in delivering innovative cloud-based solutions.

About CloudMile

CloudMile, a leading AI and cloud technology company in Asia, focuses on digital transformation for its corporate clients and driving growth. Leveraging machine learning and big data analysis, CloudMile assists over 700+ clients corporates with business forecasts and industrial upgrades. CloudMile has earned 200+ accreditations, with 60+ Google Cloud professional certifications. Being a Google Cloud Premier Partner across multiple product and engagement models, CloudMile has Specializations for Machine Learning – Services, Data Analytics – Services, Cloud Migration – Services, Infrastructure – Services, Work Transformation – Enterprise, Security – Services and Infrastructure – Training.

The company has become Google Cloud Managed Service Provider (MSP) covering Taiwan, Hong Kong and Singapore as well as the Google Cloud Public Sector Partner of the Year for the APAC Region in 2020.

For more information, visit https://www.mile.cloud/ or follow CloudMile on LinkedIn CloudMile Inc.

Media Contact
Company Name: GlobalPR Agency
Contact Person: Mei Chang
Email: Send Email
Phone: +886-2-2882-5577
City: Taipei City
Country: Taiwan
Website: https://www.globalpr.agency

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: CloudMile Wins MongoDB Emerging Markets Partner of the Year Award for Driving Data Innovation and Business Impact in Southeast Asia

Marshall County Paving is a Top Rated Paving Company

Marshall County Paving is the best paving business in the area. The company is known for providing excellent services and being dedicated to quality. Marshall County Paving is known for its professionalism and skill. It provides a wide range of paving services to meet the needs of household, business, and industrial customers.

Lewisburg, TN – Marshall County Paving is an expert in asphalt paving. They have built a name for excellence by consistently delivering high-quality results. The skilled Paving Contractor Lewisburg team brings a lot of experience and technical knowledge to every job, so they can make sure that all of their paving projects are done correctly and last a long time. The use of cutting-edge tools and high-quality products further shows the company’s commitment to meeting high standards.

Marshall County Paving’s business attitude is based on making sure customers are happy. The Paving Company Lewisburg makes sure that every job is finished on time, on Budget, and to the highest standards of craftsmanship by planning and carrying it out with great care. Marshall County Paving works hard on all kinds of jobs, no matter how big or small. They do everything from paving driveways and parking lots to resurfacing roads and keeping them in good shape.

Marshall County Paving does more than build new pavements. They also fix and maintain old pavements to make them last longer. Driveway Paving Lewisburg takes a proactive approach that includes thorough assessments and custom solutions made to deal with specific problems. This stops the problems from getting worse and improves the general safety and look of the driveway.

About Marshall County Paving

Marshall County Paving is the go-to Asphalt Paving company. Its reputation for dependability, quality, and customer-focused service makes the company the best choice for all paving needs in Marshall County and the nearby areas.

Media Contact
Company Name: Marshall County Paving
Contact Person: Dylan Huffman
Email: Send Email
Phone: (931) 600-5966
City: Lewisburg
State: TN 37091
Country: United States
Website: https://marshallcountypaving.com/

Sunny Hills Assisted Living Facility Homestead Sweeps Highlands County Awards, Solidifying Position as Premier Assisted Living Provider in Florida

sunny hills awarded best assisted living facility in Florida

Sunny Hills Assisted Living Facility Homestead Sweeps Highlands County Awards, Solidifying Position as Premier Assisted Living Provider in Florida

HOMESTEAD, FL – June 25, 2024 – In a landmark achievement for assisted living in Florida, Sunny Hills Assisted Living Facility Homestead has been honored with an unprecedented five awards from Highlands County, cementing its status as the premier assisted living facility in the Sunshine State.

The prestigious accolades include Best ALF Overall, Best ALF Memory Care, Best ALF Skilled Nurses, Best Large ALF, and Best Independent Living ALF. This clean sweep across diverse categories underscores Sunny Hills’ commitment to excellence in every facet of senior care.

Robert P. Lowry, founder of Sunny Hills, expressed his gratitude: “These awards reflect our unwavering dedication to providing top-tier assisted living services in Florida. Our team’s passion and expertise have made Sunny Hills a beacon of quality care in Homestead and beyond.”

The recognition comes at a time when the demand for high-quality assisted living in Florida continues to grow. According to the Florida Health Care Association, the state’s 65+ population is projected to grow by 79% between 2020 and 2040, highlighting the critical need for exceptional senior care facilities.

Sunny Hills’ success is built on a foundation of personalized care and cutting-edge amenities. The facility’s memory care program, recognized as the best in the county, employs evidence-based techniques to support residents with cognitive challenges. A recent study by the Alzheimer’s Association found that specialized memory care can slow cognitive decline by up to 30%, underscoring the importance of Sunny Hills’ award-winning approach.

The Best ALF Skilled Nurses award speaks to the facility’s commitment to medical excellence. With a staff-to-resident ratio that exceeds state requirements by 25%, Sunny Hills ensures that each resident receives personalized attention and care.

As the Best Large ALF, Sunny Hills proves that scale doesn’t compromise quality. The facility’s 150,000 square foot campus, nestled in the heart of Homestead at 25268 SW 134th Ave, offers a diverse range of activities and amenities. From gourmet dining options to state-of-the-art fitness facilities, residents enjoy a lifestyle that promotes both physical and mental well-being.

The Independent Living ALF award highlights Sunny Hills’ ability to cater to seniors at various stages of life. This versatility is crucial in Florida’s diverse senior care landscape, where, according to the Florida Assisted Living Association, over 70% of residents transition between care levels during their stay.

Industry experts have taken note of Sunny Hills’ achievements. Dr. Maria Rodriguez, a gerontologist at the University of Miami, commented: “Sunny Hills is setting new standards for assisted living in Florida. Their holistic approach to care, combining medical expertise with lifestyle enrichment, is exactly what our aging population needs.”

The impact of these awards extends beyond accolades. Sunny Hills has seen a 40% increase in inquiries since the announcement, indicating a strong demand for quality assisted living options in Florida. This surge aligns with statewide trends, as the Florida Senior Living Association reports a 15% year-over-year increase in assisted living occupancy rates.

As Sunny Hills Assisted Living Facility Homestead basks in the glow of its recent honors, the focus remains on the future. Plans are underway to expand services and potentially open new locations across Florida, bringing the award-winning Sunny Hills experience to more seniors in need of quality care.

For those seeking the best in assisted living, Florida now has a clear frontrunner. Sunny Hills Assisted Living Facility Homestead stands ready to welcome new residents into its award-winning community, where excellence in care meets the warmth of home.

For more information about Sunny Hills Assisted Living Facility Homestead or to schedule a tour, please contact:+1 305-258-2222 or Email at jconfident.sunnyhills@gmail.com

About Sunny Hills Assisted Living Facility Homestead:

Founded by Robert P. Lowry, Sunny Hills Assisted Living Facility Homestead is a leading provider of senior care services in Florida. Offering a range of living options from independent living to specialized memory care, Sunny Hills is committed to enhancing the lives of seniors through personalized care, engaging activities, and a supportive community environment.

Media Contact
Company Name: Sunny Hills Assisted Living Facility Homestead
Contact Person: Robert P. Lowry
Email: Send Email
Phone: +13052582222
Address:25268 SW 134th Ave, Homestead
City: Miami-Dade County
State: Florida 33032
Country: United States
Website: www.alfsunnyhills.com/